Sugi Predict

Sugi Predict / Compounds / SCHEMBL420503

SCHEMBL420503

SCHEMBL420503

CC(C)(C)OC(=O)N1CCCN1C(=O)OCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 2/20 0.51
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ HTT P42858 1/20 0.46
▸ HTR2C P28335 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ CTSL P07711 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ PARP1 P09874 1/20 0.45
▸ PDK1 Q15118 1/20 0.43
▸ PDK2 Q15119 1/20 0.43
▸ PDK3 Q15120 1/20 0.43
▸ PDK4 Q16654 1/20 0.43
▸ CTSB P07858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4924522 0.97 MEN1 (0.48) CTSKMEN1KMT2ANPSR1NPC1
SCHEMBL13100989 0.89 MEN1 (0.56) MEN1KMT2ANPSR1NPC1RAB9A
SCHEMBL13101483 0.88 HTR2C (0.49) MEN1KMT2ANPSR1NPC1RAB9A
SCHEMBL10189350 0.88 MEN1 (0.53) MEN1KMT2ANPSR1NPC1RAB9A
SCHEMBL4740593 0.87 NPC1 (0.43) CTSKMEN1KMT2ANPSR1NPC1
SCHEMBL16612115 0.85 KMT2A (0.58) CTSKMEN1KMT2ANPSR1NPC1
SCHEMBL16847349 0.85 MEN1 (0.57) MEN1KMT2ANPSR1NPC1RAB9A
SCHEMBL4850529 0.85 HTR2C (0.45) MEN1KMT2ANPSR1NPC1RAB9A
SCHEMBL9358292 0.84 ALDH1A1 (0.53) CTSKMEN1KMT2ANPSR1NPC1
SCHEMBL14030742 0.84 KMT2A (0.54) CTSKMEN1KMT2ANPSR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025243042-A1 COMPOUNDS FOR THE INHIBITION OF CYCLOPHILIN D THE UNIVERSITY OF LIVERPOOL (GB) 2025-11-27 — — WO disclosed
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-09-18 — — US disclosed
WO-2025090658-A2 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-05-01 — — WO disclosed
CN-116813705-A Peptide compound, application thereof and composition containing peptide compound 凯惠科技发展(上海)有限公司 2023-09-29 — — CN disclosed
CN-109206481-B Peptide compound, application thereof and composition containing peptide compound 尚华医药科技(江西)有限公司 2023-08-18 — — CN disclosed
US-9017673-B2 Peptide analogues comprising at least one type of aminoacylaza-$g(b)<sp>3</sp>and the use thereof, in particular for therapy CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-04-28 — — US disclosed
EP-2417126-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-07-02 — — EP disclosed
US-8404670-B2 Histamine H3 inverse agonists and antagonists and methods of use thereof SUNOVION PHARMACEUTICALS INC. (US) 2013-03-26 — — US disclosed
EP-2475664-A2 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2012-07-18 — — EP disclosed
EP-2475662-A2 HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2012-07-18 — — EP disclosed
EP-1631586-B1 PEPTIDE ANALOGUES COMPRISING AT LEAST ONE TYPE OF AMINOACYL AZA-BETA 3 AND THE USE THEREOF, IN PARTICULAR FOR THERAPY CENTRE NAT RECH SCIENT (FR) 2007-08-22 — — EP disclosed
US-20060281686-A1 Aza-peptides LABORATOIRES SERONO SA (CH) 2006-12-14 — — US disclosed
CN-1249066-C 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines PROCTER & GAMBLE (US) 2006-04-05 — — CN disclosed
EP-1631586-A2 PEPTIDE ANALOGUES COMPRISING AT LEAST ONE TYPE OF AMINOACYL AZA-BETA 3 AND THE USE THEREOF, IN PARTICULAR FOR THERAPY CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2006-03-08 — — EP disclosed
EP-1567546-A2 AZA-PEPTIDES Applied Research Systems ARS Holding N.V. (AN) 2005-08-31 — — EP disclosed
WO-2004111086-A2 PEPTIDE ANALOGUES COMPRISING AT LEAST ONE TYPE OF AMINOACYL AZA-$G(B)3 AND THE USE THEREOF, IN PARTICULAR FOR THERAPY CENTRE NATIONAL DE LA RECHERCHE SCIENTIQUE (FR) 2004-12-23 — — WO disclosed
CN-1556811-A 6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines — 2004-12-22 — — CN disclosed
WO-2004050689-A2 AZA-PEPTIDES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-06-17 — — WO disclosed
US-6069163-A SUBSTITUTED AZAPEPEPTIDE ACIDS ARE SUITABLE FOR USE IN THE TREATMENT OF ASTHMA, ALLERGIES, INFLAMMATION, MULTIPLE SCLEROSIS, AND OTHER INFLAMMATORY AND AUTOIMMUNE DISORDERS MERCK & CO., INC. (US) 2000-05-30 — — US disclosed
WO-1999020272-A1 AZAPEPTIDE ACIDS AS CELL ADHESION INHIBITORS MERCK & CO., INC. (US) 1999-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF CDK2, CDK20, CDK1 CTSK 2370/4885MEN1 2982/4885KMT2A 85/4885
US-20060281686-A1 Aza-peptides APP, APBA1, IAPP CTSK 1417/4885MEN1 1667/4885KMT2A 742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.